CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough
Drugmaker CSPC Pharma gets the green light to produce China’s first homegrown mRNA vaccine, but the breakthrough comes too late in the pandemic to impress investors Key Takeaways: News of…
Riding Covid Vaccine Highs, CanSino Plans Swiss Listing
The first vaccine stock to be listed in the both Mainland China and Hong Kong will issue global depositary receipts (GDRs) in SwitzerlandKey Takeaways:After successful listings in Shanghai and Hong…
After Ditching Promising Drug, Everest Medicines Bets on mRNA
The drug maker surprised investors last year when it halted its tie-up with Gilead to develop the breast cancer drug Trodelvy. Now it says it will focus on mRNA vaccinesKey…
FAST NEWS: CanSino’s Inhaled Covid Booster Gets China Green Light
The latest: CanSino Biologics Inc. (6185.HK; 688185.SH) announced on Sunday that China’s National Medical Products Administration (NMPA) have given emergency use authorization for its inhaled recombinant Covid-19 vaccine for use as…
RELATED ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
